FigureAsia 35 Under 35 · AI
Pranav Rajpurkar
Age 30 · Academic researcher and laboratory leader · India and United States; medical-AI research with international clinical relevance
Designing Medical Artificial Intelligence Around Clinical Reality
- Age at the edition eligibility date
- 30
- Field
- Medical imaging, multimodal clinical AI and evaluation
- Country or region
- India and United States; medical-AI research with international clinical relevance
- FigureAsia U35 Assessment
- 92.9 / 100
Profile
Career and documented record
Pranav Rajpurkar works on a question medicine cannot avoid: how should general-purpose AI enter a system where evidence, workflow and accountability matter as much as benchmark accuracy? His research spans diagnostic imaging, multimodal foundation models and new environments for testing clinical agents over time.
Pranav Rajpurkar is an associate professor of biomedical informatics at Harvard Medical School, where his laboratory develops and evaluates AI for medicine. His earlier first-author work on CheXNet helped establish deep learning as a serious method for chest-radiograph interpretation. More recently, he has argued that medical AI must move beyond isolated prediction towards systems that can integrate modalities, specialists and sequential decisions. MedVersa, published in NEJM AI in 2026, embodies that direction: a language-model-orchestrated generalist system for multiple medical-imaging tasks. In a retrospective reader study reported by his laboratory, radiologists judged generated chest-X-ray reports clinically equivalent to human reports in 64% of cases overall and 91% of normal cases. Those findings do not establish patient benefit or clinical approval. Rajpurkar also co-authored a 2026 Nature Medicine perspective proposing a clinical-environment simulator with hospital and patient engines for dynamic evaluation of AI agents. Companion work in Nature Biomedical Engineering set out a generalist–specialist collaboration framework and examined large reasoning models as potential thinking machines for medicine. Across these projects, his emphasis is consistent: assess AI not as a detached benchmark entrant, but as one component of a clinical system with changing information, expert roles and consequences.
FigureAsia selection
Why Pranav Rajpurkar is on the list
FigureAsia selected Rajpurkar for sustained technical and conceptual leadership in one of AI’s highest-stakes domains. CheXNet established his early ability to define a field-facing benchmark; MedVersa advances a generalist imaging architecture; his 2026 frameworks confront harder questions of workflow, simulation and specialist oversight. The selection recognises both performance and restraint. His strongest recent clinical figures come from retrospective reader evaluation, and his broader proposals are research agendas—not evidence that autonomous medical agents are ready for unsupervised care.
Verified work
The 2025–26 record
Verified contribution 01
Co-author of MedVersa, published in NEJM AI in 2026, a language-model-orchestrated generalist system spanning multiple medical-imaging tasks.
Verified contribution 02
In its retrospective reader evaluation, the team reported that radiologists judged generated chest-X-ray reports clinically equivalent to human reports in 64% of cases overall and 91% of normal cases.
Verified contribution 03
Co-author of a 2026 Nature Medicine perspective proposing hospital and patient engines for dynamic simulation and evaluation of clinical AI agents.
Verified contribution 04
Co-author of 2026 Nature Biomedical Engineering work on generalist–specialist collaboration and on large reasoning models in medicine.
Field context
The work in its field
Medical imaging and clinical-workflow constraints cross borders, while specialist shortages differ sharply by region. Rajpurkar’s open research, multi-institutional collaborations and system-level evaluation proposals give hospitals, universities and regulators a shared vocabulary for testing medical AI beyond narrow accuracy scores.
Asia’s vast and unevenly resourced health systems stand to gain from rigorous medical AI, but also bear substantial deployment risk; Rajpurkar’s evaluation-first approach is directly relevant.
FigureAsia U35 Assessment
Assessment breakdown
92.9out of 100
Defining contribution
23.5 / 25
A completed piece of work, institution or system that materially changes what the field can do.
Demonstrated impact and reach
18 / 20
Observable adoption, scientific use, policy consequence or operational reach, with self-reported metrics labelled as such.
Personal agency and attribution
13.8 / 15
Evidence that the individual shaped the result, separated from team, employer and investor halo.
Technical or institutional originality
13.95 / 15
A new method, product form, research direction, governance mechanism or deployment model.
Durability and field-shaping influence
9.4 / 10
The likelihood that the contribution will remain useful beyond a single news cycle or model release.
Evidence integrity and responsible practice
9.5 / 10
The quality of the record, the precision of claims and the seriousness with which limitations and harms are addressed.
Asia–world relevance
4.75 / 5
A documented connection to Asia, impact on Asian systems, or clear importance to the region’s place in the international field.